Hematopoietic stem cell transplantation does not increase the risk of infection‐related complications for pediatric patients with Hodgkin and non‐Hodgkin lymphomas: A multicenter nationwide study

Hodgkin (HL) and non‐Hodgkin lymphoma (NHL) represent a spectrum of lymphoid malignancies that are often curable with currently applied treatment regimens; however, 15%‐30% of lymphoma patients still suffer from relapsed or refractory (rel/ref) disease. Although hematopoietic stem cell transplantation (HSCT) improves outcomes of second‐line therapy for lymphoma in childhood, the complication rates in this group of patients, especially infectious complications (IC), remain unclear.

[1]  J. Wachowiak,et al.  Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology , 2018, Leukemia & lymphoma.

[2]  M. Albayrak,et al.  Is antimicrobial prophylaxis necessary for lymphoma patients? A single centre, real-life experience , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  J. Wachowiak,et al.  Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  I. Riaz,et al.  A Review of Autologous Stem Cell Transplantation in Lymphoma , 2017, Current Hematologic Malignancy Reports.

[5]  M. Relling,et al.  Infection-related complications during treatment for childhood acute lymphoblastic leukemia , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  James R. Anderson,et al.  Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. , 2016 .

[7]  G. Lyman,et al.  Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma , 2016, Expert opinion on drug safety.

[8]  André Ricardo Araújo da Silva,et al.  Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. , 2015, Jornal de pediatria.

[9]  T. Lehrnbecher,et al.  Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia , 2014, Expert review of hematology.

[10]  M. Bassetti,et al.  Multidrug-resistant bacteria: what is the threat? , 2013, Hematology. American Society of Hematology. Education Program.

[11]  A. Reiter.  Non-Hodgkin Lymphoma in Children and Adolescents , 2013, Klinische Pädiatrie.

[12]  R. Takimoto,et al.  Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.

[13]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Attarbaschi,et al.  Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Dupuis,et al.  Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia , 2009, The Pediatric infectious disease journal.

[16]  J. Styczyński,et al.  Prevention of infectious complications in pediatric HSCT , 2008, Bone Marrow Transplantation.

[17]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Escherich,et al.  Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia , 2008, Pediatric blood & cancer.

[19]  B. Ding,et al.  Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. , 2007, Clinical lymphoma & myeloma.

[20]  G. Lyman,et al.  Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.